Table 4.
Novel approaches and strategies for attenuated erysipelas vaccines.
| Vaccine type | E. rhusiopathiae strain | Specifics | Dose (route)a | Challenge serovar | Species | No. of animals used | Survival | References |
|---|---|---|---|---|---|---|---|---|
| Attenuated (vectored) | YS-1 | R1b and R2 regions of the P97 adhesin of M. hyopneumoniae strain E-1 fused with SpaA | 2 (IN) 1 (IN) |
1a | Pigs | 3 3 |
100% 0% |
(154) |
| Koganei 65-0.15 | 7 (oral) | 1a | Pigs | 8 | 100% | (155) | ||
| Attenuated | Δ432 | 651 mutants were screened in mice to determine attenuation and protective immunity | 2 (oral) 1 (oral) |
1a | Pigs | 10 10 |
100% 90% |
(150) |
a
Administration route: IN, intranasal.
b
R1 and R2 are repeat regions.